Elderly Cancer Patients
Elderly Cancer Patients - Related Videos
08:03
Generation of Prostate Cancer Patient Derived Xenograft Models from Circulating Tumor Cells
0 Views •
Cited by 59 •
2015
This manuscript details a method used to generate prostate cancer patient derived xenografts (PDXs) from circulating tumor cells (CTCs). The generation of PDX models from CTCs provides an alternative experimental model to study prostate cancer; the most commonly diagnosed tumor and a frequent cause of death from cancer in men.
03:21
Zebrafish Patient-Derived Xenograft (zPDX): A Cancer Model
0 Views •
2023
This video describes the technique to create a zebrafish patient derived xenograft model. In the sample protocol, we assess the efficiency of the drugs Gemcitabine and Navitoclax on the pancreatic tumor xenograft model.
12:16
Patient Derived Cell Culture and Isolation of CD133+ Putative Cancer Stem Cells from Melanoma
0 Views •
Cited by 22 •
2013
This article describes the preparation of freshly obtained melanoma tissue into primary cell cultures, and how to remove contaminations of erythrocytes and fibroblasts from the tumor cells. Finally, we describe how CD133+ putative melanoma stem cells are sorted from the CD133- bulk using Magnetic Activated Cell Sorting (MACS).
09:04
Establishment and Maintenance of Patient-derived Prostate Cancer Organoids: A Detailed Experimental Protocol
0 Views •
Cited by 1 •
2025
Prostate cancer heterogeneity and treatment resistance remain challenges. We describe a protocol for generating patient-derived organoids (PDOs) that preserve key parental tumor characteristics. This standardized model supports drug screening and precision medicine advancements.
09:29
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
0 Views •
Cited by 23 •
2016
Utilizing patient-derived tumors in a subcutaneous preclinical model is an excellent way to study the efficacy of novel therapies, predictive biomarker discovery, and drug resistant pathways. This model, in the drug development process, is essential in determining the fate of many novel anti-cancer therapies prior to clinical investigation.
FAQs
Age-related changes in organ function, drug metabolism, immune responses, mobility, cognition, and nutrition can alter how a person tolerates therapy. These factors may influence the risks and benefits of surgery, chemotherapy, radiation, or immunotherapy, even when two patients have similar cancers. Recognizing such differences helps clinicians adapt treatment planning to the patient’s overall health and functional reserve.
Cancer stage describes the extent of malignancy, but it does not fully indicate whether a patient can safely tolerate intensive treatment. Frailty, other illnesses, reduced mobility, cognitive changes, and nutritional problems may increase treatment burden or complication risk. Considering these factors together supports a more individualized balance between disease control, treatment safety, symptom management, and the patient’s broader goals.
Geriatric assessment examines health domains that routine tumor evaluation may not capture, including organ function, comorbidities, mobility, cognition, and nutritional status. Its findings provide context for judging likely treatment tolerance and support decisions about the intensity and goals of care. This approach helps clinicians identify vulnerabilities that could otherwise complicate therapy or reduce independence.
Assessment considers the malignancy and its stage together with age-related health changes, coexisting conditions, frailty, mobility, cognition, and nutritional status. Clinicians also consider the patient’s treatment goals and the potential effects of surgery, chemotherapy, radiation, or immunotherapy. Reviewing these elements before treatment helps identify an approach that addresses the cancer while accounting for safety, symptoms, and daily functioning.
Shared decision-making weighs expected disease control against the risks and burdens of treatment, while incorporating the patient’s goals and priorities. For one person, aggressive therapy may be acceptable; for another, preserving independence or limiting complications may be more important. Integrating clinical assessment with these preferences produces a care plan that reflects both medical considerations and quality-of-life priorities.
Cancer care that combines tumor evaluation with geriatric assessment can support symptom management, complication prevention, and preservation of independence. It may also improve the fit between treatment intensity and the patient’s health status, rather than focusing only on malignancy control. This broader perspective is especially relevant when age-related vulnerabilities, comorbidities, or frailty could affect daily function and quality of life.